JCR Pharmaceuticals Co., Ltd. (TYO:4552)

JCR Pharmaceuticals Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	13,196	18,756	13,278	30,733	26,260
Short-Term Investments	-	-	-	244	-
Cash & Short-Term Investments	13,196	18,756	13,278	30,977	26,260
Cash Growth	-29.64%	41.26%	-57.14%	17.96%	134.61%
Receivables	12,236	14,934	11,137	15,585	8,183
Inventory	21,758	20,933	18,514	14,636	13,554
Other Current Assets	3,866	2,958	4,873	990	548
Total Current Assets	51,056	57,581	47,802	62,188	48,545
Property, Plant & Equipment	37,410	30,040	32,681	26,782	17,172
Long-Term Investments	10,442	9,819	9,443	2,769	3,094
Other Intangible Assets	2,960	3,496	3,652	2,960	3,232
Long-Term Deferred Tax Assets	2,985	1,288	1,357	2,433	1,739
Other Long-Term Assets	2	2	2	2	2
Total Assets	104,855	102,226	94,937	97,134	73,784
Accounts Payable	590	890	1,563	1,324	2,932
Accrued Expenses	1,216	1,130	1,088	1,004	913
Short-Term Debt	23,005	8,950	16,800	15,150	12,850
Current Portion of Long-Term Debt	3,050	-	500	-	-
Current Income Taxes Payable	3,097	4,402	2,836	11,104	2,646
Other Current Liabilities	13,030	14,763	12,975	13,472	9,687
Total Current Liabilities	43,988	30,135	35,762	42,054	29,028
Long-Term Debt	12,050	14,350	5,500	2,950	5,250
Other Long-Term Liabilities	418	364	339	173	154
Total Liabilities	57,422	45,752	42,525	46,047	35,230
Common Stock	9,061	9,061	9,061	9,061	9,061
Additional Paid-In Capital	10,392	10,384	10,384	10,994	10,941
Retained Earnings	31,191	37,278	34,273	33,241	20,904
Treasury Stock	-5,066	-2,963	-2,978	-3,600	-3,685
Comprehensive Income & Other	1,463	2,417	1,421	1,186	1,159
Total Common Equity	47,041	56,177	52,161	50,882	38,380
Minority Interest	392	297	251	205	174
Shareholders' Equity	47,433	56,474	52,412	51,087	38,554
Total Liabilities & Equity	104,855	102,226	94,937	97,134	73,784
Total Debt	38,105	23,300	22,800	18,100	18,100
Net Cash (Debt)	-24,909	-4,544	-9,522	12,877	8,160
Net Cash Growth	-	-	-	57.81%	234.97%
Net Cash Per Share	-201.16	-36.24	-76.27	103.67	65.74
Filing Date Shares Outstanding	121.84	124.8	124.78	123.76	123.61
Total Common Shares Outstanding	121.84	124.8	124.78	123.76	123.61
Working Capital	7,068	27,446	12,040	20,134	19,517
Book Value Per Share	386.10	450.12	418.04	411.14	310.48
Tangible Book Value	44,081	52,681	48,509	47,922	35,148
Tangible Book Value Per Share	361.81	422.11	388.77	387.23	284.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.